New antibody combo shows promise for Hard-to-Treat cancers
Disease control
Recruiting now
This early-stage trial tests a new drug called DT-7012, alone or with another cancer drug, in adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors. About 125 people will take part.
Phase: PHASE1, PHASE2 • Sponsor: Domain Therapeutics Australia Pty Ltd • Aim: Disease control
Last updated May 17, 2026 03:16 UTC